Mutated protein A domains and uses thereof
By mutation and fusion of the C domain of protein A at specific sites, a protein A separation matrix with improved alkali resistance was formed, which solved the problem of insufficient stability of protein A affinity chromatography media in an alkaline environment, and achieved the High stability and load residue under high alkaline conditions reduce the cost of antibody purification.
Patent Information
- Application Number
- CN202311341738.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-09
- Filing Date
- 2023-10-17
- Publication Date
- 2024-12-06
AI Technical Summary
The existing protein A affinity chromatography media are insufficient in basic environments, resulting in high antibody purification costs and difficulty in maintaining load residues under high alkaline conditions, affecting its large-scale scale in the field of bioaffinity chromatography. use.
By performing amino acid mutations at specific sites in the C domain of protein A, especially substitution mutations at positions 3, 29 and 36, a mutant polypeptide with increased alkali resistance is formed and fused into a fusion protein or Recombinant protein A, bound to the solid support, forms an isolated matrix with improved alkali resistance.
It significantly improves the alkali resistance of protein A under 0.4, 0.5 or 0.6M NaOH conditions, ensures that high stability and load residues remain after long-term soaking, and reduces the cost of antibody purification.
Smart Images

Figure BDA0004497482190000171 
Figure BDA0004497482190000181 
Figure HDA0004497482200000011
Abstract
Description
Technical Field
[0001] The invention belongs to the fields of biology and chemistry, and in particular relates to a mutant protein A domain and an application thereof. Background Art
[0002] Protein A is a cell wall protein of Staphylococcus aureus and is widely used as an affinity chromatography medium for purifying immunoglobulins. Natural protein A has five domains that bind to immunoglobulins, especially IgG, from the N-terminus to the C-terminus, namely the E domain, the D domain, the A domain, the B domain, and the C domain. Studies have shown that the five homologous domains of wild-type protein A can bind to immunoglobulins and Fc fusion proteins. For immunoglobulin G (IgG), each domain shows a strong affinity for the Fc region of IgG subclasses IgG1, IgG2, and IgG4.
[0003] During use, protein A affinity chromatography media will adsorb impurities such as host proteins, pigments, nucleic acids, endotoxins and viruses, and need to be cleaned in place (CIP) with NaOH to remove impurities. Therefore, improving the stability of protein A affinity chromatography media in alkaline environments is the key to enabling its large-scale use in the field of biological affinity chromatography. Currently, mainstream protein A affinity chromatography media such as Cytiva's MabSelect SuRe are alkali-resistant chromatography media that can withstand 0.1-0.5M NaOH cleaning, thereby efficiently and cost-effectively removing impurities attached to the filler. However, there is still a need to further improve the alkali resistance of protein A affinity chromatography media to further reduce the cost of antibody purification.
[0004] Brief description of the invention
[0005] The present invention provides a mutant polypeptide of the C domain which has improved alkali resistance and improved residual loading after alkali treatment compared with the C domain of natural protein A.
[0006] Specifically, in a first aspect, the present invention provides a polypeptide having a substitution mutation at one or more positions selected from position 3, position 29 and position 36 compared to the native C domain of protein A shown in SEQ ID NO: 1 alone.
[0007] In some embodiments, the polypeptide has a substitution mutation at position 3 compared to the native C domain of protein A shown in SEQ ID NO: 1 alone; in some embodiments, the polypeptide has a substitution mutation at position 29 compared to the native C domain of protein A shown in SEQ ID NO: 1 alone; in some embodiments, the polypeptide has a substitution mutation at position 36 compared to the native C domain of protein A shown in SEQ ID NO: 1; in some embodiments, the polypeptide has substitution mutations at positions 29 and 36 compared to the native C domain of protein A shown in SEQ ID NO: 1 alone.
[0008] In some embodiments, the substitution mutation at position 3 is that asparagine is substituted with valine, glycine, alanine, leucine or isoleucine. Preferably, the substitution mutation at position 3 is that asparagine is substituted with leucine.
[0009] In some embodiments, the substitution mutation at position 3 is N3V, N3G, N3A, N3L or N3I, preferably, the substitution mutation at position 3 is N3L.
[0010] In some embodiments, the substitution mutation at position 29 is that glycine is substituted with tryptophan, histidine, methionine or tyrosine, preferably, the substitution mutation at position 29 is that glycine is substituted with tryptophan.
[0011] In some embodiments, the substitution mutation at position 29 is G29W, G29H, G29M or G29Y. Preferably, the substitution mutation at position 29 is G29W.
[0012] In some embodiments, the substitution mutation at position 36 is aspartic acid substituted with valine, glycine, alanine, leucine or isoleucine, preferably, the substitution mutation at position 36 is aspartic acid substituted with valine.
[0013] In some embodiments, the substitution mutation at position 36 is D36V, D36G, D36A, D36L or D36I. Preferably, the substitution mutation at position 36 is D36V.
[0014] The second aspect of the present invention provides a polypeptide, which is composed of the following (i), (ii) and (iii): (i) the polypeptide described in any embodiment of the first aspect of the present invention, (ii) one or more coupling elements at the C-terminus or N-terminus of the amino acid sequence of the polypeptide in (i), and optionally (iii) residues from the cleaved signal transduction sequence.
[0015] In some embodiments, the coupling element is selected from the group consisting of: a cysteine residue, a plurality of lysine residues, and a plurality of histidine residues.
[0016] The third aspect of the present invention provides a fusion protein, which is formed by the fusion of 2-8 polypeptides. Preferably, the fusion protein is formed by the fusion of 4 polypeptides, wherein the polypeptide is the polypeptide described in any embodiment of the first aspect or any embodiment of the second aspect of the present invention.
[0017] In some embodiments, in the fusion protein, the 2-8 polypeptides are different from each other, partially identical to each other, or completely identical to each other. Preferably, the 2-8 polypeptides are completely identical to each other.
[0018] In some embodiments, each of the polypeptides contained in the fusion protein contains at least N3V, N3G, N3A, N3L or N3I mutations, and preferably also contains the substitution mutation at position 29 described herein, preferably the substitution mutation at position 29 is G29W, G29H, G29M or G29Y mutation, and preferably also contains the substitution mutation at position 36 described herein, preferably the substitution mutation at position 36 is D36V, D36G, D36A, D36L or D36I.
[0019] In some embodiments, a linker sequence is present or absent between the polypeptides.
[0020] In some embodiments, the linker sequence is a linker sequence containing glycine (G) and serine (S).
[0021] In some embodiments, the C-terminus or N-terminus of the fusion protein further comprises one or more coupling elements.
[0022] In some embodiments, the coupling element is selected from the group consisting of: a cysteine residue, a plurality of lysine residues, and a plurality of histidine residues.
[0023] In some embodiments, the fusion protein further comprises residues from the cleaved signaling sequence.
[0024] The fourth aspect of the present invention provides a recombinant protein A, wherein the C domain of the recombinant protein A is the polypeptide described in any embodiment of the first aspect of the present invention.
[0025] The fifth aspect of the present invention provides an isolated nucleic acid molecule, the polynucleotide sequence of the nucleic acid molecule is selected from:
[0026] (1) a polynucleotide sequence encoding the polypeptide according to any embodiment of the first aspect, the polypeptide according to any embodiment of the second aspect, the fusion protein according to any embodiment of the third aspect, or the recombinant protein A according to any embodiment of the fourth aspect of the present invention;
[0027] (2) A polynucleotide sequence complementary to the polynucleotide sequence described in (1).
[0028] The sixth aspect of the present invention provides a nucleic acid construct, which contains the nucleic acid molecule described in the fifth aspect of the present invention.
[0029] In some embodiments, the nucleic acid construct is an expression cassette.
[0030] In some embodiments, the nucleic acid construct is an expression vector or a cloning vector.
[0031] The seventh aspect of the present invention further provides an expression system, which contains the nucleic acid construct described in any embodiment of the sixth aspect of the present invention.
[0032] In one or more embodiments, the expression system is a host cell.
[0033] The eighth aspect of the present invention provides a separation matrix, which comprises the polypeptide described in any embodiment of the first aspect of the present invention, the polypeptide described in any embodiment of the second aspect, the fusion protein described in any embodiment of the third aspect and / or the recombinant protein A described in any embodiment of the fourth aspect coupled to a solid support.
[0034] In some embodiments, the polypeptide, fusion protein or recombinant protein A is coupled to the solid support via a thioether bond.
[0035] The ninth aspect of the present invention provides a chromatographic column comprising the separation matrix described in the eighth aspect of the present invention.
[0036] The tenth aspect of the present invention provides a method for separating Fc-containing proteins (such as immunoglobulins), the method comprising the step of contacting a sample containing Fc-containing proteins with the polypeptide described in any embodiment of the first aspect of the present invention, the polypeptide described in any embodiment of the second aspect, the fusion protein described in any embodiment of the third aspect and / or the recombinant protein A described in any embodiment of the fourth aspect.
[0037] In some embodiments, the method comprises the step of contacting a sample containing a protein containing Fc with the separation matrix described in any embodiment of the eighth aspect of the present invention or the chromatographic column described in the ninth aspect. Preferably, the method further comprises, after contacting, washing the separation matrix and eluting the protein containing Fc from the separation matrix with an eluent.
[0038] In an eleventh aspect, the present invention provides use of the polypeptide described in any embodiment of the first aspect, the polypeptide described in any embodiment of the second aspect, the fusion protein described in any embodiment of the third aspect, and / or the recombinant protein A described in any embodiment of the fourth aspect in separating Fc-containing proteins, or in preparing a separation matrix or chromatographic column for separating Fc-containing proteins. DETAILED DESCRIPTION OF THE INVENTION
[0040] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a preferred technical solution.
[0041] Herein, "antibody" and "immunoglobulin" are used interchangeably and have well-known meanings in the art. The antibody or immunoglobulin described herein also includes antibody fragments, and fusion proteins or conjugates containing antibody fragments, as long as such fragments, fusion proteins or conjugates contain the Fc portion of the antibody and can be separated and purified by binding to protein A. The antibody fragment may be a functionally active fragment thereof.
[0042] In the present specification, amino acid residues are also described by the following abbreviated symbols: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), valine (Val or V), and any amino acid residue (Xaa or X). In the present specification, the amino acid sequence of a peptide is generally described with the amino terminus (hereinafter referred to as N-terminus) on the left and the carboxyl terminus (hereinafter referred to as C-terminus) on the right.
[0043] In the present invention, examples of amino acid groups having side chains with similar chemical properties include aliphatic amino acids, aromatic amino acids, and heterocyclic amino acids. Aliphatic amino acids include 1) neutral amino acids containing one amino group and one carboxyl group: glycine, alanine, valine, leucine, and isoleucine; 2) hydroxyl-containing amino acids: serine and threonine; 3) sulfur-containing amino acids: cysteine and methionine; 4) amide-containing amino acids: asparagine and glutamine; 5) acidic amino acids containing one amino group and one carboxyl group: aspartic acid and glutamic acid; 6) basic amino acids containing two amino groups and one carboxyl group: lysine and arginine. Aromatic amino acids include phenylalanine and tyrosine. Heterocyclic amino acids include tryptophan, histidine, and proline.
[0044] The present invention finds that a mutant polypeptide of the C domain obtained by performing substitution mutation on at least one of the 3rd, 29th and 36th positions of the C domain of natural protein A, and a fusion protein obtained by fusing the four mutant polypeptides have significantly improved alkaline stability during alkaline cleaning compared to commercially available protein A, and still has good alkaline resistance after being immersed in 0.4, 0.5 or 0.6M NaOH for 72 hours, thereby completing the present invention.
[0045] Specifically, the present invention provides a polypeptide, which has a substitution mutation at one or more positions selected from position 3, position 29 and position 36 compared to the native C domain of protein A shown in SEQ ID NO: 1. The substitution mutation does not affect the original structure of the C domain, but significantly improves the alkaline stability of the obtained mutant.
[0046] The polypeptide of the present invention can be directly used as a ligand for binding and separating immunoglobulins. Therefore, in some embodiments, the polypeptide also contains one or more coupling elements for coupling the polypeptide to a solid support at its C-terminus or N-terminus. Suitable coupling elements are well known in the art, including but not limited to cysteine residues, multiple lysine residues (such as 3-15 or 5-10) and multiple histidine residues (such as 3-15 or 5-10). The coupling element can be a cysteine residue and is located at the C-terminus of the polypeptide, so that the thiol group in the cysteine residue can be used to react with the electrophilic group on the solid support to couple the polypeptide to the solid support. The coupling element can be directly connected to the polypeptide, or it can be connected to the N or C-terminus of the polypeptide through a linker. The linker can increase the flexibility of the resulting product. The linker can be a linker conventionally used in the art, and the linker does not affect the binding activity of the polypeptide. An exemplary linker is a linker sequence containing G and S or consisting of G and S, usually 2-20 amino acid residues. A linker sequence containing G and S or consisting of G and S can increase the spatial separation between components and / or allow intramolecular interactions between components. Exemplary linker sequences are (GS)n, (GSS)n, (GSSS)n, and (GSSSS)n, where n can be an integer from 2 to 10, but the total linker length is generally not more than 20 amino acid residues. The polypeptide may also include a plurality of (e.g., within 15, within 10, or within 5) amino acid residues at the N-terminus, which are derived from residues in the cloning process or from a signal transduction sequence. As a specific example, the polypeptide may include AQ at the N-terminus.
[0047] The present invention also provides a fusion protein, which is formed by fusing 2-8 of the above-mentioned polypeptides of the present invention. The polypeptides forming the fusion protein may be all different, partially identical, or all identical. The polypeptides may be directly connected to each other through the peptide bonds at the C-terminus and the N-terminus, or any two polypeptides may be connected through a linker. The linker may be a linker conventionally used in the art, and the linker does not affect the binding activity of the polypeptide. An exemplary linker is a linker sequence containing G and S or consisting of G and S, which is usually 2-20 amino acid residues long. Exemplary linker sequences are such as (GS)n, (GSS)n, (GSSS)n, and (GSSSS)n, where n may be an integer of 2-10, but the total length of the linker is usually not more than 20 amino acid residues.
[0048] The fusion protein can be used as a ligand for binding and separating immunoglobulins. Therefore, in some embodiments, the fusion protein also contains one or more coupling elements for coupling the fusion protein to a solid support at its C-terminus or N-terminus. Suitable coupling elements are well known in the art, including but not limited to cysteine residues, multiple lysine residues (such as 3-15 or 5-10) and multiple histidine residues (such as 3-15 or 5-10). The coupling element can be 1 cysteine residue, and is located at the C-terminus of the fusion protein, so that the thiol group in the cysteine residue can be used to react with the electrophilic group on the solid support to couple the fusion protein to the solid support. The coupling element can be directly connected to the polypeptide, or it can be connected to the N or C-terminus of the polypeptide through a joint. The joint can be a joint conventionally used in the art, and the joint does not affect the binding activity of the polypeptide. An exemplary joint is a joint sequence containing G and S or composed of G and S, usually 2-20 amino acid residues. Exemplary linker sequences include (GS)n, (GSS)n, (GSSS)n, and (GSSSS)n, where n can be an integer from 2 to 10, but the total linker length is usually no more than 20 amino acid residues. The fusion protein may also include multiple (e.g., less than 15, less than 10, or less than 5) amino acid residues at the N-terminus, which are derived from the cloning process or from residues of a signal transduction sequence. As a specific example, the fusion protein may include AQ at its N-terminus.
[0049] The present invention also provides a recombinant protein A, whose C domain is a polypeptide described in any embodiment of the present invention. The remaining domains of the recombinant protein A can be the E domain, D domain, A domain and B domain (or Z domain, which is a modified domain of the B domain) of protein A known in the art, including natural E domain, D domain, A domain and B domain and known mutations but retaining biological activity E domain, D domain, A domain and / or B domain (such as Z domain). In addition to the C domain using the polypeptide of the present invention, mutations or modifications made to the rest of protein A known in the art can be used for the recombinant protein A of the present invention.
[0050] The present invention also includes polypeptides, fusion proteins and recombinant proteins A having at least 85% sequence identity with the polypeptides, fusion proteins or recombinant proteins A described in any embodiment of the present invention, and having substitution mutations described in any embodiment of the present invention at one or more amino acid positions selected from the group corresponding to positions 3, 29 and 36 of SEQ ID NO: 1. Herein, "at least 85% identity" with respect to amino acid sequences and nucleotide sequences refers to an identity of more than 85%, preferably an identity of more than 90%, more preferably an identity of more than 95%, further preferably an identity of more than 97%, further preferably an identity of more than 98%, and even more preferably an identity of more than 99%. The identity between the two aligned sequences can be calculated using tools well known in the art, including BLASTP for amino acid sequence alignment.
[0051] The present invention also includes nucleic acid molecules encoding the aforementioned polypeptides, fusion proteins and recombinant protein A and their complementary sequences. The present invention includes all forms of nucleic acid molecules of the present invention, including RNA and DNA. It should be understood that the complementary sequence described herein refers to a complementary sequence having a length substantially identical to that of the nucleic acid molecule.
[0052] The nucleic acid construct containing the nucleic acid molecule or its complementary sequence is also included in the scope of the present invention. The nucleic acid construct can be an expression cassette, which contains a promoter, the nucleic acid molecule and a transcription termination sequence. Promoters and transcription termination sequences are well known in the art and can be appropriately selected by those skilled in the art according to the selected host cell for expressing the polypeptide, fusion protein or recombinant protein A.
[0053] In some embodiments, the nucleic acid construct is a vector, including an expression vector and a cloning vector. An expression vector is a vector suitable for expressing an exogenous gene such as a nucleic acid molecule encoding a polypeptide, a fusion protein or a recombinant protein A in a host cell, including a prokaryotic expression vector and a eukaryotic expression vector. Eukaryotic expression vectors include yeast expression vectors, mammalian cell expression vectors and insect cell expression vectors. Cloning vectors are used to amplify target genes (such as nucleic acid molecules encoding polypeptides, fusion proteins or protein A described in the present invention) in host cells. Cloning vectors include plasmid vectors, phage vectors, viral vectors, and vectors formed by combining them with each other or with other genomic DNA. The most commonly used host cell in molecular cloning is Escherichia coli.
[0054] The present invention also provides an expression system comprising a nucleic acid molecule, a nucleic acid construct or a vector disclosed herein. The expression system can be, for example, a Gram-positive or Gram-negative prokaryotic host cell system, such as an Escherichia coli or Bacillus modified to express a polypeptide, a fusion protein or a recombinant protein A of the present invention. In some embodiments, the expression system is a eukaryotic host cell system, such as a yeast, such as Pichia pastoris or Saccharomyces cerevisiae.
[0055] Pichia pastoris is a new expression system that uses methanol as the sole carbon source and has high biosafety.
[0056] In some embodiments, the Pichia pastoris is Pichia pastoris GS115.
[0057] The present invention also provides a separation matrix. The separation matrix of the present invention can be used to separate immunoglobulins or Fc-containing proteins. The separation matrix of the present invention contains the polypeptide, fusion protein and / or recombinant protein A according to any embodiment of the present invention coupled to a solid support. Due to the improved alkaline stability of the polypeptide, fusion protein and recombinant protein A of the present invention, the separation matrix of the present invention can withstand high alkaline conditions (e.g., 0.5-1.0 M NaOH) during cleaning.
[0058] The solid support in the separation matrix of the present invention may be a solid support known in the art and used in the separation of immunoglobulins or Fc-containing proteins.
[0059] Herein, the shape of the solid support can be any shape such as particles, membranes, plates, tubes, needles, fibers, etc. The solid support of the present invention can be a porous material, or a non-porous material. In some embodiments, the solid support is a porous or non-porous beaded form or a granular form. The matrix in the beaded form or granular form can be used as a packed bed or in a suspended form. The suspended form includes an expanded bed in which the particles or beads move freely.
[0060] When the solid support is a particle, the particle size is preferably 20-200 μm. For example, when the solid support is a synthetic polymer, the particle size is preferably 20-100 μm, more preferably 30-80 μm. When the solid support is a polysaccharide, the particle size is preferably 50-200 μm, more preferably 60-150 μm. The "particle size" in this specification refers to the volume average particle size measured by the laser diffraction method according to ISO 13320 and JIS Z 8825-1.
[0061] Examples of solid supports include, but are not limited to, polymers containing multiple hydroxy groups, such as polysaccharides. Polysaccharides include dextran, starch, cellulose, pullulan, agar and agarose, etc. In a preferred embodiment, the solid support comprises agar or agarose.
[0062] In some embodiments, the solid support of the present invention is a synthetic polymer with a hydrophilic surface. For example, such polymers can be polymers having hydroxyl, carboxyl, aminocarbonyl, amino or oligoethyleneoxy or polyethyleneoxy groups on the outer surface (and also on the inner surface if present) by hydrophilization, preferably synthetic polymers such as copolymers obtained by cross-linking multifunctional monomers such as multifunctional (meth) acrylates and divinylbenzene. Exemplary synthetic polymers include polyvinyl alcohol, polystyrene, polystyrene divinylbenzene, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamide and polymethacrylamide, etc. In the case where the polymer surface is hydrophobic, the surface can be hydrophilized to expose the hydrophilic groups to the surrounding aqueous liquid.
[0063] In some embodiments, the solid support of the present invention comprises a support of inorganic nature, including but not limited to silicon dioxide, zirconium oxide, and the like.
[0064] In some embodiments, the solid support of the present invention is in the form of a surface, a chip, a capillary, or a filter, such as a membrane or the like.
[0065] In the present invention, the polypeptide, fusion protein and recombinant protein A described in the present invention can be connected to the corresponding solid support through the thiol group, amino group and / or carboxyl group contained therein by conventional coupling technology. Commonly used coupling reagents include but are not limited to diepoxide, epichlorohydrin, CNBr and N-hydroxysuccinimide. A spacer can be introduced between the solid support and the polypeptide, fusion protein and recombinant protein A described in the present invention, which can promote their chemical coupling with the solid support.
[0066] In some embodiments, the polypeptide, fusion protein or recombinant protein A of the present invention can be coupled to a solid support via a thioether bond. In some embodiments, the polypeptide, fusion protein or recombinant protein A of the present invention is coupled via the cysteine at its C-terminus, wherein the cysteine thiol group is effectively coupled to an electrophilic group such as an epoxy group, a halohydrin group, etc. on the solid support to form a thioether bridge coupling.
[0067] In the separation matrix of the present invention, the concentration of the binding ligand (such as the polypeptide, fusion protein and / or recombinant protein A described in the present invention) coupled to the solid support is generally 5-20 mg / ml, for example 5-15 mg / ml. The amount of the coupled binding ligand can be controlled by adjusting the concentration of the polypeptide, fusion protein and / or recombinant protein A used in the coupling process, the coupling conditions used and / or the pore structure of the solid support used.
[0068] The present invention also provides a chromatography column, which contains the separation matrix of the present invention. Usually, the separation matrix of the present invention is filled in a chromatography column.
[0069] The present invention also provides a method for separating Fc-containing proteins (such as immunoglobulins), the method comprising the step of contacting the polypeptide, fusion protein and / or recombinant protein A described in any embodiment herein with a sample containing Fc-containing proteins. In some embodiments, the method comprises the step of contacting the sample with the separation matrix or chromatographic column described in any embodiment herein.
[0070] More specifically, in some embodiments, the method comprises:
[0071] (1) contacting a sample containing an Fc-containing protein with the separation matrix described in any embodiment of the present invention;
[0072] (2) washing the separation matrix;
[0073] (3) eluting the Fc-containing protein from the separation matrix;
[0074] (4) Cleaning the separation matrix.
[0075] Herein, the sample may be any sample containing Fc-containing proteins (especially immunoglobulins). Preferably, the immunoglobulin described herein refers to IgG.
[0076] The washing liquid for washing the separation matrix, the eluent for eluting the protein, and the cleaning liquid for cleaning the separation matrix used in the method are all washing liquids, eluents, and cleaning liquids conventionally used in the art (especially in the field of protein A chromatography). For example, the washing liquid can be a PBS buffer. The eluent can be a solution or buffer with a pH ≤ 5, and preferably, the pH of the eluent is 2.5-5 or 3-5. In some embodiments, the pH of the eluent is 11 or higher, for example, the pH of the eluent is 11-14 or 11-13. In some embodiments, a citrate solution, such as a sodium citrate solution, is used for elution. The cleaning liquid is usually alkaline, and its pH can be 13-14. In some embodiments, the cleaning liquid is a sodium hydroxide solution or a potassium hydroxide solution, and its concentration is 0.1-2.0M, for example, 0.5-2.0M or 0.5-1.0M.
[0077] In some embodiments, the method described herein further comprises the step of recovering the eluate and further separating and purifying it. Further separation and purification can be performed by anion or cation exchange chromatography, composite ion exchange chromatography and / or hydrophobic interaction chromatography, etc., depending on the separated protein.
[0078] The present invention also provides use of the polypeptide, fusion protein and protein A described in any embodiment of the present invention in separating and purifying Fc-containing proteins, or in preparing a separation matrix for separating and purifying Fc-containing proteins.
[0079] In the present invention, the chromatography medium containing the mutated protein A of the present invention is agarose gel microspheres.
[0080] The mutant protein A or fusion protein described herein has a high affinity to IgG molecules and can be used for separation and purification of IgG molecules and immunodetection.
[0081] In the present invention, "alkali resistance" refers to the ability of the mutant protein A to remain stable after being exposed to an alkaline solution (e.g., 0.1, 0.2, 0.3, 0.4 or 0.5 M or higher NaOH solution) for a period of time or a certain number of times. Preferably, the period of time is 30 minutes, 1 hour, 1.5 hours or 2 hours. The number of times is 50 times, 100 times or more.
[0082] In the present invention, the mutant fusion protein or protein A may also be connected with a signal peptide or a tag for convenient purification, such as a histidine tag, a GST tag, and the like.
[0083] The sequence described in this article is as follows:
[0084] SEQ ID NO:1 Sequence of the native C domain of protein A
[0085] ADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILA EAKKLNDAQAPK
[0086] SEQ ID NO:2 Sequence of the mutant C domain of protein A G29W
[0087] ADNKFNKEQQNAFYEILHLPNLTEEQRNWFIQSLKDDPSVSKEILA EAKKLNDAQAPK
[0088] SEQ ID NO:3 Sequence D36V of the mutant C domain of protein A
[0089] ADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKVDPSVSKEILA EAKKLNDAQAPK
[0090] SEQ ID NO:4 Sequence of the mutant C domain of protein A G29W, D36V
[0091] ADNKFNKEQQNAFYEILHLPNLTEEQRNWFIQSLKVDPSVSKEILA EAKKLNDAQAPK
[0092] SEQ ID NO:5 Sequence of the mutant C domain of protein A: N3L, G29W, D36V
[0093] ADLKFNKEQQNAFYEILHLPNLTEEQRNWFIQSLKVDPSVSKEILAEAKKLNDAQAPK BRIEF DESCRIPTION OF THE DRAWINGS
[0094] Figure 1 The sequence alignment results of the five domains of Protein A are shown.
[0095] Figure 2 A schematic diagram showing the positions of amino acids susceptible to fragmentation after NaOH treatment (amino acid side chains are shown).
[0096] Figure 3 The stability results of the fusion protein of the present invention and the 1 M standard protein on the market after being immersed in different concentrations of NaOH for 3 hours are shown.
[0097] Figure 4 The results of protein residues of the fusion protein of the present invention and 1M standard protein after being immersed in 0.5M NaOH for different time periods are shown.
[0098] Figure 5 The alkali resistance results of the fusion protein of the present invention after being immersed in 0.4, 0.5 and 0.6 M NaOH conditions for different time periods are shown.
[0099] Figure 6 The results of the loading attenuation tests of the fusion protein of the present invention, Jibaikang's brand recombinant protein A (P315-g), and the leading product on the market, MabSelect SuRe LX, are shown.
[0100] Figure 7 The results of alkaline resistance of the double-site mutant tandem repeat fusion protein after soaking in 0.4, 0.5, 0.6M, 0.7 and 0.8M NaOH for 24 hours are shown. The size of the marker band is 25 kDa. DETAILED DESCRIPTION
[0101] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.
[0102] Example 1 Peptide sequence design
[0103] 1. First, the five domain sequences of protein A were aligned. Figure 1 As shown in Figure 2, the five domain sequences are highly consistent and bind to IgG mainly in the helix 1 and helix 2 regions (red boxes).
[0104] 2. Under alkaline conditions, Gln-Ser (QS) sequences (referring to any QS sequence appearing in the five domains) and Gly-Glu (GE) sequences (referring to any GE sequence appearing in the five domains) are easily cleaved under protease conditions. Therefore, amino acid modification can be performed on the QS and GE sequences appearing in each domain. After the cleavage sites are treated with NaOH, the protein is easily degraded. The main cleavage area is the QS junction (such as Figure 1 The C domain is the only one of the five regions that does not have a basic cleavage site and is the most resistant to NaOH. Therefore, mutations were performed around the sequence of the C domain.
[0105] 3. Asn (N) and Gln (Q) are highly sensitive to deamidation reactions, so avoid mutating amino acids to N and Q. If the a-helix (generally referring to two or three a-helices, meaning that if one a-helix is unstable, the protein is easily degraded) is unstable, the alkali stability of the protein will decrease. Avoid mutating proline (P) to other amino acids to maintain protein stability. Cysteine (C) and lysine (K) are conducive to the immobilization of affinity ligands, so avoid mutating C and K to other amino acids.
[0106] 4. Asn-Gly is an alkali-sensitive sequence, and Asn substitution can improve the chemical stability of proteins. Glycine and alanine have no helix-forming properties and are relatively small, so they can replace other amino acids.
[0107] 5. The binding function of protein A to IgG exists in helix 1 and helix 2, but does not involve helix 3 and loop 2. Therefore, when mutating the amino acids in this area, attention should be paid to the binding ability of protein A to IgG.
[0108] 6. In the C domain, the asparagine side chain of Asn-28 plays a role in the interaction with the IgG-Fc region, so mutations in Asn-28 should be avoided. Gly-29 is conserved in all protein A domains, but it does not participate in the interaction with IgG-Fc, so G29 can be modified. Substitution with amino acids containing larger side chain groups can increase the stability of proteins in alkaline environments, so G can be replaced with amino acids such as histidine (H), tryptophan (W), methionine (M), and tyrosine (Y).
[0109] 7. In the C domain, the aspartic acid (position 36) at the end of the α-helix 2 is easily degraded. Replacing the aspartic acid residue with other amino acids can significantly improve the chemical stability of the protein domain under alkaline conditions. Valine (V) has a positive effect on the alkaline stability of its C domain, so D can be replaced by V.
[0110] In addition, increasing intramolecular interactions can also increase the tolerance of proteins to the external environment. Taking the above factors into consideration, we give priority to the transformation of the C domain to N3L, G29W, and D36V. The sequence polymerization ligand of the C domain is designed to form four tandem repeats, and then 6 histidines and 1 cysteine are added to the N and C termini respectively to replace the asparagine residue at position 3, which can increase the alkali resistance during in situ cleaning (in situ cleaning refers to the removal of impurities such as precipitates and denatured substances from the purification system). The present invention selects substitution mutations at positions 3, 29, and 36 of the natural C domain of protein A shown in SEQ ID NO:1.
[0111] Example 2 Construction of recombinant plasmid
[0112] The sequence obtained in Example 1 was synthesized (the sequence of the present invention has 6 histidine tags added to the N-terminus) (the sequence was synthesized by Shanghai Biotech), and then the synthesized sequence was connected to the vector pET-30a (+) (purchased from Biotech, item number B540185) through recombinant NcoⅠ / XhoⅠ. The recombination process used a recombination kit (purchased from Novozyme, item number: C112), and the recombinant product was added to E. coli BL21 competent cells for transformation. Positive clones were screened for amplification, and plasmids were extracted using a plasmid extraction kit (purchased from Novozyme, item number: DC201-01). The plasmids can be used for subsequent experiments after they are correctly sequenced.
[0113] Example 3 Protein expression and purification
[0114] (1) The positive clones with correct sequencing were spread on a plate. After overnight incubation at 37°C, the positive clones were picked and transferred to 5 mL of liquid LB medium with a kana concentration of 100 mg / L, and incubated at 37°C, 250 rpm for 12 hours.
[0115] (2) Expand the culture system to 800 mL and continue to culture on a shaker. When the OD600 value of the bacterial solution reaches 0.8-1.0, place the bacterial solution in ice water and cool it to 16°C.
[0116] (3) Add IPTG to a working concentration of 0.2 mM and induce overnight at 18°C and 250 rpm.
[0117] (4) Centrifuge at 5000 rpm for 15 min at 4°C, discard the supernatant, and add 10 mL of pre-cooled Lysis buffer (0.2 mg / mL lysozyme, 1 mM PMSF, 500 mM NaCl, 20 mM PB, 1 mM MgCl) per 2 g of bacterial cells. 2 ) Resuspend the cells. Use an ultrasonic disruptor to disrupt the cells, sonicate for 2 seconds each time, stop for 4 seconds, and use 20% power for a total of 30 minutes. Centrifuge at 4°C, 10,000 g for 30 minutes.
[0118] (5) After equilibration, nickel column filler (purchased from Qiagen, catalog number: 30210) was mixed with the protein supernatant and incubated in a 4°C refrigerator for 1 hour.
[0119] (6) First, use 50 mM imidazole to elute the impurity protein, and then use 200 mM imidazole to elute the target protein, and store the protein in a -80°C refrigerator. The purification efficiency of the present invention is: 30-40 mg of purified protein can be obtained per liter of bacterial liquid (the OD600 value of the bacterial liquid is 1).
[0120] Example 4 Alkali resistance test
[0121] The purified protein (the protein has four tandem repeats of SEQ ID NO: 4) was soaked in NaOH of different concentrations and time, and then the alkaline resistance was tested. The size of the protein obtained in the present invention is 28 kDa.
[0122] Take equal amounts of protein A sample of the present invention and standard control protein sample (Zhuhai Jibaikang Biotechnology Co., Ltd., recombinant alkali-resistant protein A, item number P318-1g), mix with different concentrations of NaOH, and incubate at 37°C for different times. Take out the protein sample, add 5× loading buffer (final concentration is 1X) (250mM Tris-HCl (pH 6.8), 10% (W / V) SDS, 0.5% (W / V) BPB, 50% (V / V) glycerol, 5% (W / V) β-mercaptoethanol), and place in a metal bath at 100°C for 5min.
[0123] Alkali resistance detection is performed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The gel portion of SDS-PAGE is generally divided into two parts: a concentrated gel and a separation gel. The sample is concentrated to a certain extent in the concentrated gel before entering the separation gel. The concentration of the selected separation gel depends on the specific conditions of the sample to be separated. Generally, the larger the molecular weight of the protein, the smaller the concentration of the selected separation gel. Due to the presence of ionic detergents and strong reducing agents in the sample solution and gel, the influence of charge factors can be ignored, so the electrophoretic mobility of protein subunits mainly depends on the size of the subunit molecular weight.
[0124] SDS-PAGE electrophoresis was performed at a constant voltage of 120 V for 1.5-2 h, and Coomassie Brilliant Blue R-250 staining (thermal staining) was performed at the end of electrophoresis, followed by decolorization. The decolorized gel was photographed and the electrophoresis results were analyzed.
[0125] Table 1 Gel composition of SDS-polyacrylamide gel electrophoresis
[0126] Reagents 12% separation gel 15% separation gel 5% stacking gel Liquid A 4mL 7.5mL 1.34mL Liquid B (or Liquid C) 2.5mL 3.75mL 2mL Ultrapure water 3.5mL 3.75mL 4.6mL 10% ammonium persulfate 50μL 50μL 60μL TEMED 5μL 7.5μL 10μL Total volume 10mL 10mL 8mL
[0127] First, the stability of the protein of the present invention and the 1M standard protein on the market after soaking in different concentrations of NaOH for 3 hours was compared. The preliminary results showed that the protein of the present invention had better alkaline resistance in NaOH concentrations below 0.6M. The 1M standard protein only had better alkaline resistance in 0.5M NaOH ( Figure 3 ). Combined Figure 3 Based on the results, we detected the residual protein content of the protein of the present invention and 1M standard protein after soaking in 0.5M NaOH for different time periods. Figure 4 As shown, the results show that the protein residue percentages of the protein of the present invention at 6 hours, 12 hours and 24 hours are 91%, 87%, 82% respectively, while the protein residue percentages of the 1M standard protein at 6 hours, 12 hours and 24 hours are 78%, 70%, 69% respectively. The results show that the protein of the present invention has stronger alkali resistance than the 1M standard protein. Next, we tested the protein of the present invention by soaking in 0.4, 0.5 and 0.6M NaOH conditions for different time periods. The results showed that the protein of the present invention still had a good alkali resistance effect after soaking in 0.6M NaOH for 24 hours ( Figure 5 ).
[0128] Example 5 Loading attenuation test under alkali solution immersion conditions
[0129] 1. Sample Preparation
[0130] Take agarose microspheres with a concentration of 4% that have been cross-linked twice (L. Zhao, Y. Huang, K. Zhu, Z. Miao, J. Zhao, X. J. Che, D. Hao, R. Zhang, G. Ma, Manipulation of pore structure during manufacture of agarose microspheres for bioseparation, Eng. Life Sci. 20 (2020) 504-513. https: / / doi.org / 10.1002 / elsc.202000023.) as raw materials for coupling reaction. The coupling reaction is as follows: (1) First, 10 parts of microspheres, 10 parts of organic solvent (DMSO), 1 part of epichlorohydrin, and 1 part of NaOH aqueous solution (concentration in the range of 5%-20%) are fully mixed by weight. (2) The above-mentioned substances that have been fully mixed are reacted at 37 degrees Celsius for 1-3 hours. (3) The above-mentioned mixed solution is washed and filtered with appropriate cleaning agents (such as anhydrous ethanol) and water in sequence, and the washed microspheres are collected. The microspheres are basically activated, and the epoxy groups with a certain concentration (such as 20-30μmol / g) are qualified for coupling with the protein A ligand. (4) The collected protein A solution (generally 10-20mg / mL in concentration, the solution uses 20mM PB buffer, and the pH value is controlled at about 9.5) is fully mixed with the microspheres and fully reacted at 25 degrees Celsius for 10-24 hours. (5) After the reaction, the microspheres were collected and washed, and then reacted with 0.5 M ethanolamine (pH = 9.5) at 25 degrees Celsius for two hours to completely block the remaining epoxy groups and avoid nonspecific adsorption. (6) The microspheres were thoroughly washed with deionized water until neutral.
[0131] 2. Purification
[0132] (1) Column loading: Fill 0.9g of the prepared microspheres into the prepared pre-loaded column (product name: 1mL empty column tube, Shanghai Chenqiao Biotechnology Co., Ltd.). After the microspheres (filler) have settled naturally, use external force to compress the column height by 10-15%. (2) Connect the pre-loaded column with a certain volume of microspheres (1.02mL-1.05mL) to a purifier (the purifier is generally used to measure the dynamic loading capacity of microspheres (Suzhou Insai Intelligent Technology Co., Ltd., model: Unique AutoPre100DD)). (3) First, use 0.1M NaOH to clean and disinfect the chromatography column, using 3-5 column volumes of NaOH solution. (4) Use 3 to 5 column volumes of 50mM Tris-HAc (pH=7.4) to balance the chromatography column. (5) Use 15mL of IgG solution (Luoyang Deji Biotechnology Co., Ltd.) for bypass penetration and measure its maximum absorption value at a UV wavelength of 280nm. (6) Use IgG solution to load the column, and monitor the changes in its UV absorption during the process. Generally speaking, the UV absorption will remain at a very low level for a long time, and then slowly increase as the column gradually becomes saturated until the absorbance reaches 10% of the UV absorption value measured in step (5). The total time of this step is t, the IgG concentration used is N, and the flow rate is v. The formula for calculating its dynamic loading at 10% penetration is: DBC = t*v*N. (7) Use 50mM NaAc-HAc (pH = 3.7) for elution until the elution peak disappears. And use 3 to 5 column volumes of purified water to replace the original elution equilibrium solution (50mM NaAc-HAc (pH = 3.7), where the specific formula is: HAc: 45.6mM, NaAc: 4.4mM). (8) Use 3-5 column volumes of 0.5M NaOH to pass the column, and ensure that the regeneration peak disappears completely, and keep the column in this concentration of NaOH solution for 24 hours. (9) Use 3-5 column volumes of purified water to completely replace the NaOH solution in the column. (10) Repeat steps (3)-(9) 3 times. Record the loading after 24 hours, 48 hours, and 72 hours of NaOH soaking.
[0133] The present invention uses the protein of the present invention, Jibaikang's brand recombinant protein A, and the leading product on the market, MabSelect SuRe LX, to compare the results. Figure 6 shown.
[0134] The initial load of the first measurement is marked as 100%, and the dynamic change of the load with the cleaning time is statistically analyzed. It can be observed that the alkali resistance of the present invention and the recombinant alkali-resistant protein of Jibaikang are better than the leading product on the market, namely MabSelect Sure LX.
[0135] Table 2 Comparison of the binding capacity of the protein of the present invention, Jibaikang's brand recombinant protein A, and the leading product on the market MabSelectSuRe LX after alkali treatment
[0136]
[0137]
[0138] Example 6 Alkali resistance test of double-site mutation tandem repeat fusion protein
[0139] Referring to the experimental method of Example 2-4, the alkali resistance of the double-site mutation (G29W, D36V) tandem repeat fusion protein was determined. Figure 7 As shown, compared with the 1M standard protein on the market (Jibaikang recombinant alkali-resistant protein), the double-site mutation (G29W, D36V) tandem repeat fusion protein has better alkali resistance.
[0140] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A polypeptide, characterized in that Compared with the native C domain of protein A shown in SEQ ID NO: 1 alone, the polypeptide has a substitution mutation at one or more positions selected from position 3, position 29 and position 36, preferably, the polypeptide has a substitution mutation at position 29, preferably, the polypeptide has a substitution mutation at position 36, preferably, the polypeptide has substitution mutations at positions 29 and 36, preferably, the polypeptide has substitution mutations at positions 3, 29 and 36, and preferably, the substitution mutations improve the alkali resistance of protein A.
2. The polypeptide according to claim 1, characterized in that The substitution mutation at position 3 is that asparagine is substituted with valine, glycine, alanine, leucine or isoleucine, preferably, the substitution mutation at position 3 is that asparagine is substituted with leucine, or the substitution mutation at position 29 is that glycine is substituted with tryptophan, histidine, methionine or tyrosine, preferably, the substitution mutation at position 29 is that glycine is substituted with tryptophan, or the substitution mutation at position 36 is that aspartic acid is substituted with valine, glycine, alanine, leucine or isoleucine, preferably, the substitution mutation at position 36 is that aspartic acid is substituted with valine.
3. A polypeptide, characterized in that The polypeptide consists of the following (i), (ii) and (iii): (i) a polypeptide according to claim 1 or 2, (ii) one or more coupling elements at the C-terminus or N-terminus of the amino acid sequence of the polypeptide in (i) to couple the polypeptide to a solid support, and optionally (iii) residues from a cleaved signal transduction sequence (such as AQ), preferably, the coupling element is selected from: a cysteine residue, a plurality of (preferably 3-15 or 5-10) lysine residues and a plurality of (preferably 3-15 or 5-10) histidine residues.
4. A fusion protein, characterized in that The fusion protein comprises the polypeptide according to any one of claims 1 to 3, preferably, the fusion protein comprises 2 to 8 polypeptides according to any one of claims 1 to 3, more preferably, the fusion protein comprises 4 polypeptides according to any one of claims 1 to 3, preferably, the fusion protein further comprises one or more of the E domain, D domain, A domain and B domain of wild-type protein A.
5. The fusion protein according to claim 4, characterized in that When the fusion protein comprises 2 to 8 polypeptides according to any one of claims 1 to 3, the 2 to 8 polypeptides are different from each other, partially identical to each other, or completely identical to each other. Preferably, the 2 to 8 polypeptides are completely identical to each other.
6. The fusion protein according to claim 4 or 5, characterized in that There may or may not be a linker sequence between the polypeptide, the E domain, the D domain, the A domain and the B domain. Preferably, the linker sequence is a linker sequence containing glycine (G) and serine (S). More preferably, the linker sequence is (GS)n, (GSS)n, (GSSS)n and (GSSSS)n, where n can be an integer from 2 to 10. Preferably, the total length of the linker does not exceed 20 amino acid residues.
7. The fusion protein according to any one of claims 4 to 6, characterized in that The C-terminus or N-terminus of the fusion protein further comprises one or more coupling elements. Preferably, the coupling element couples the polypeptide to a solid support. More preferably, the coupling element is selected from the group consisting of: a cysteine residue, a plurality of (preferably 3-15 or 5-10) lysine residues and a plurality of (preferably 3-15 or 5-10) histidine residues.
8. The fusion protein according to any one of claims 4 to 7, characterized in that The fusion protein also includes residues from the cleaved signal transduction sequence.
9. Recombinant protein A, characterized in that The C domain of the recombinant protein A is a polypeptide according to any one of claims 1 to 3.
10. An isolated nucleic acid molecule, characterized in that The polynucleotide sequence of the nucleic acid molecule is selected from: (1) a polynucleotide sequence encoding a polypeptide according to any one of claims 1 to 3, a fusion protein according to any one of claims 4 to 8, or a recombinant protein A according to claim 9; (2) A polynucleotide sequence that is completely complementary to the polynucleotide sequence described in (1).
11. A nucleic acid construct, characterized in that The nucleic acid construct contains the nucleic acid molecule according to claim 10, preferably, the nucleic acid construct is an expression vector or a cloning vector.
12. A cell, characterized in that The cell comprises the nucleic acid construct according to claim 11.
13. A separation matrix, characterized in that The separation matrix comprises the polypeptide according to any one of claims 1 to 3, the fusion protein according to any one of claims 4 to 8, or the recombinant protein A according to claim 9 coupled to a solid support.
14. The separation matrix according to claim 13, characterized in that The polypeptide, fusion protein or recombinant protein A is coupled to the solid support via a thioether bond. Preferably, the solid support is selected from a polymer containing polyhydroxy groups, a synthetic polymer having a hydrophilic surface and an inorganic support. The polymer containing polyhydroxy groups is, for example, a polysaccharide selected from dextran, starch, cellulose, pullulan, agar and agarose; the synthetic polymer having a hydrophilic surface is a polymer having hydroxyl groups, carboxyl groups, aminocarbonyl groups, amino groups or oligoethyleneoxy groups or polyethyleneoxy groups on the outer surface (and, if present, also on the inner surface) by hydrophilization treatment, and the synthetic polymer is selected from polyvinyl alcohol, polystyrene, polystyrene divinylbenzene, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamide and polymethacrylamide; the inorganic support is selected from silica and zirconium oxide.
15. A chromatographic column, characterized in that The chromatography column contains the separation matrix according to claim 13 or 14.
16. A method for separating Fc-containing proteins (such as immunoglobulins), characterized in that: The method comprises the step of contacting a sample containing an Fc-containing protein with a polypeptide according to any one of claims 1 to 3, a fusion protein according to any one of claims 4 to 8, or a recombinant protein A according to claim 9, or the method comprises the step of contacting a sample containing an Fc-containing protein with a separation matrix according to claim 13 or 14 or a chromatographic column according to claim 15. Preferably, the method further comprises, after contacting, washing the separation matrix and eluting the Fc-containing protein from the separation matrix with an eluent.
17. Use of the polypeptide according to any one of claims 1 to 3, the fusion protein according to any one of claims 4 to 8, or the recombinant protein A according to claim 9 in separating Fc-containing proteins, or in preparing a separation matrix or chromatographic column for separating Fc-containing proteins.
